Can a new drug heal stomach ulcers faster?
NCT ID NCT07730138
First seen Jul 28, 2026 · Last updated Jul 29, 2026 · Updated 1 time
Summary
This phase 3 trial tests whether an experimental drug called DWP14012 (fexuprazan) can heal stomach ulcers as well as or better than the standard treatment lansoprazole. About 384 adults with at least one active gastric ulcer will receive either DWP14012 or lansoprazole daily for up to 8 weeks. Doctors will use an endoscope to check whether the ulcers have healed.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- an experimental drug called DWP14012 (fexuprazan) compared to the standard drug lansoprazole
- What this could lead to
- If it works, this could offer a new treatment option for healing stomach ulcers.
- What could go wrong
- This is a phase 3 trial, but it is still experimental. The drug may not prove as effective as lansoprazole, and side effects are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 3
Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.
- Participants
-
About 384 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Oct 2026
An estimate. Start dates often move.
- Expected to finish
-
Oct 2028
An estimate. End dates often move.
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
19 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. At least one gastric ulcer is present, and the largest gastric ulcer measures ≥ 3 mm and ≤ 30 mm in diameter 2. The Sakita-Miwa classification of the largest gastric ulcer is A1 or A2. Exclusion Criteria: 1. Participants with a history of Zollinger-Ellison syndrome or conditions associated with gastric hypersecretion. 2. Participants who, within 30 days prior to the screening visit (Visit 1), have undergone or are scheduled to undergo major surgery that may affect gastric acid secretion. 3. Participants with a history of malignancy within 5 years prior to the screening visit (Visit 1); gastrointestinal malignancies are excluded regardless of the time elapsed. 4. Participants who, at the screening visit (Visit 1), have gastrointestinal active bleeding , esophageal stricture, ulcer-induced stenosis, pyloric stenosis, gastroesophageal varices, Barrett's esophagus (\> 3 cm), esophageal dysplasia, duodenal ulcer, refractory ulcer, perforated ulcer, or surgery-induced ulcer 5. Participants who, at the screening visit (Visit 1), have pancreatitis or inflammatory bowel disease (including Crohn's disease, ulcerative colitis, or intestinal Behçet's disease).
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Gastric ulcer are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
2 sites in 2 countries. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
RS Cipto Mangunkusumo
Jakarta, Indonesia
-
The Catholic University of Korea, Incheon St. Mary'S Hospital
Incheon, South Korea
More trials for these conditions
Other studies related to the condition(s) this trial covers.